



Mylan Schedules Investor Conference Call to Provide Update on Financial Outlook and Nebivolol

PITTSBURGH, Feb 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that it will host a conference call for investors on Thursday, March 10, 2005 at 4:30 PM (EST) in order to provide updated financial guidance for future periods, as well as an update on Nebivolol.

The investor presentation will be available live via webcast and conference call. To listen to the webcast and view the accompanying slide presentation, please go to Mylan's website at <http://www.mylan.com> and click on the webcast icon at least 15 minutes before the presentation is to begin to register and download or install any necessary audio software. If you are unable to listen to the live webcast, please access <http://www.mylan.com> at any time within seven days to listen to a replay of the webcast.

The audio presentation will also be available via teleconference, which can be accessed by dialing 1-800-967-7134 or 1-719-457-2625, for international callers. A replay will be available at 1-888-203-1112 using the conference ID code: 4223578.

About Mylan Laboratories:

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, manufacture and market an extensive line of generic and proprietary products.

For more information about Mylan, visit <http://www.mylan.com>.

Forward-looking statements:

This press release includes statements that constitute "forward-looking statements", including with regard to the planned investor conference call. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: delays or other time constraints that may necessitate changes in conference call dates; other uncertainties and matters beyond the control of management of the Company; and the other risks detailed in the periodic filings filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

CONTACTS:

Heather Bresch (Public Relations)
Mylan Laboratories Inc.
724.514.1800

Kris King (Investor Relations)
Mylan Laboratories Inc.
724.514.1800